Status:
NOT_YET_RECRUITING
Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Obesity &Amp; Overweight
Digestive Disorders
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists...
Detailed Description
Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists...
Eligibility Criteria
Inclusion
- Patient who is going to start a GLP-1 RA (semaglutide or tirzepatide) for weight management
- Men or Women
- BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 associated with one or more co-morbidities (arterial hypertension, sleep apnea, dyslipidemia, arthritis)
- Between 18 and 75 years old
- In the opinion of the investigator, the patient must have adequate support to comply with the entire study requirements as described in the protocol (e.g. transportation to and from trial site, ability to understand and fill the self-rating scales, drug compliance, availability to attend to the scheduled visits, etc…).
- Patient who agrees to be included in the study and who signs the informed consent form
- Female participants of childbearing potential must agree to use effective contraception
- Patient affiliated to a healthcare insurance plan
Exclusion
- Criteria relating to the study population:
- Patients under 18 years old
- Patient with contraindication to semaglutide or tirzepatide according to the Summary of Product Characteristics (SPC).
- Patients scheduled for bariatric surgery during the study period
- Patients who have had bariatric surgery in the last 12 months
- Patient with a current diagnosis of diabetes.
- Patients with a current diagnosis of liver cirrhosis, short bowel syndrome or inflammatory bowel disease (IBD).
- Patients with severely weakened immune system.
- Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease.
- Product criteria:
- Patient with known allergy to the product of the study
- Prohibited treatments :
- Current associated treatments or used in the last 30 days: GLP-1 RA, Anti-obesity drugs (AOD), Corticosteroids, Atypical neuroleptics, Antibiotics, Probiotics, Prebiotics
- Regulatory criteria :
- Persons deprived of their liberty by a judicial or administrative decision
- Persons under psychiatric care
- Persons admitted to a health or social institution for purposes other than research
- Adults subject to a legal protection measure (guardianship, curatorship)
- Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
- Subjects participating in other interventional research with an exclusion period still in progress at pre-inclusion
Key Trial Info
Start Date :
December 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 15 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07213323
Start Date
December 15 2025
End Date
December 15 2027
Last Update
October 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Lyon Sud
Pierre-Bénite, France, 69495